Scarica l'app Stockscreener
3.39
4.24%
-0.15
Dopo l'orario di chiusura:
3.40
0.010
+0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Altimmune Inc. stock volume spike explainedJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Real time breakdown of Altimmune Inc. stock performanceEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Using Python tools to backtest Altimmune Inc. strategiesJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Altimmune Inc. still worth holding after the dipJuly 2025 Technicals & Verified Swing Trading Watchlists - Newser
Top chart patterns to watch in Altimmune Inc.Dollar Strength & Verified Chart Pattern Trade Signals - Newser
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN
Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser
Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus
Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative
28M Patient Market: Altimmune's Novel Drug Gets FDA Fast Track for Alcohol Use Disorder Treatment Gap - Stock Titan
Trend analysis for Altimmune Inc. this weekMarket Activity Recap & Scalable Portfolio Growth Ideas - Newser
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - PR Newswire
ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. LawsuitALT - PR Newswire
Altimmune Inc. stock trend outlook and recovery pathWeekly Trend Report & Low Drawdown Investment Strategies - Newser
Using Bollinger Bands to evaluate Altimmune Inc.Market Activity Report & Expert-Curated Trade Recommendations - Newser
Levi & Korsinsky Urges Altimmune, Inc. (ALT) Shareholders to Act Before Lead Plaintiff Deadline October 6, 2025 - ACCESS Newswire
How to interpret RSI for Altimmune Inc. stockJuly 2025 Patterns & Capital Efficiency Focused Ideas - Newser
Class Action Filed Against Altimmune, Inc. (ALT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
Will Altimmune Inc. benefit from geopolitical trends2025 Growth vs Value & Daily Price Action Insights - newsyoung.net
Altimmune's Legal Storm: Navigating Risk and Opportunity in a Biotech Bet - AInvest
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Securities Class Action Risks in Biotech: Altimmune's Trial Drama and the Investor Sentiment Paradox - AInvest
What makes Altimmune Inc. stock price move sharplyGDP Growth & Verified Momentum Watchlists - mustnews.co.kr
Securities Fraud and Market Volatility in Biotech: Lessons from Altimmune's Collapse - AInvest
HC Wainwright Has Bullish Forecast for Altimmune Q3 Earnings - Defense World
B. Riley Estimates Altimmune’s Q3 Earnings (NASDAQ:ALT) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Shareholders - NewMediaWire
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - The Malaysian Reserve
Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - Eastern Progress
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - Morningstar
ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc. - Morningstar
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):